Syngene InternationalQ1 FY24

Syngene International Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹434.35P/E: 66.0Market Cap: ₹17.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

No

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Syngene expects high-teen revenue growth on a constant currency basis for FY2024.
  • Development and Manufacturing services are becoming a stronger contributor to growth.
  • Biologics manufacturing is ramping up, notably fulfilling the Zoetis contract.
  • Discovery Services and Dedicated Centers delivering steady growth, though Discovery Services growth normalizing post-pandemic catch-up.
  • The company anticipates positive bottom-line contributions from biologics manufacturing by FY27 and PAT positivity by FY29.
  • Acquisition of biologics capacity accelerates growth potential by three years, creating headroom for expansion.
  • FDA approval for the API facility in Mangalore supports scaling small molecule manufacturing.
  • Growing revenues with integrated CRO-CDMO strategy targeting 25% revenue growth as demonstrated in Q1 FY2024.
  • Investments in infrastructure, talent, and automation aimed at sustaining future growth.

See what Syngene International management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • Syngene International Limited plans to fund the biologics manufacturing facility acquisition from Stelis Biopharma through internal accruals and cash.
  • The company will maintain a strong balance sheet, low debt profile, and good safety margin for debt covenants after the acquisition.
  • Credit rating agencies CRISIL and ICRA have reaffirmed Syngene’s AA+ rating post the Stelis deal, reflecting financial strength.
  • No indications or discussions of new fundraising through debt or equity were mentioned in the transcript for the current or near future.
  • The company expects minor short-term margin dilution due to acquisition-related costs but anticipates the plant to contribute positively from FY 2027 onward.

See what Syngene International management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Syngene plans a total CAPEX spend of around US$85 million for the year, revised down from the initial guidance of US$100 million, due to the Stelis biologics acquisition avoiding planned internal CAPEX for the mammalian facility.
  • Acquired Stelis Biopharma's biologics manufacturing facility at a gross value of Rs.702 crores (~US$86 million), with an additional Rs.100 crores (~US$10 million) planned to repurpose and revalidate the facility.
  • Investment in expanding research services in Hyderabad, including purchase of 17 acres of land in Genome Valley and construction of new facilities.
  • Investment in the Mangalore API manufacturing facility (~Rs.550 crores or US$65 million) is largely complete and the facility has received FDA approval.
  • Future expansion of the biologics plant at Stelis with potential CAPEX beyond the disclosed numbers is under consideration but not decided.
  • CAPEX is expected to be fully funded through internal accruals without impacting the balance sheet adversely.

Track Syngene International — get its next earnings analysis in your feed

How does Syngene International rank vs peers in Healthcare Services?

Pro feature
ThisSyngene International
Rev 3Mar 3

How does Syngene International rank in Healthcare Services?

Compare Syngene International against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →